NFKB1 and triple-negative breast carcinoma: CIP2A-BP was shown to compete with protein phosphatase 2 (PP2A) to bind to CIP2A (cancerous inhibitor of PP2A, cancer inhibitory factor) and inhibit activation of the PI3K/AKT/NFkB pathway, preventing the migration and invasion of triple-negative breast cancer cells both in vitro and in vivo.139 Thus, CIP2A-BP represents a new microprotein target that can be overexpressed to treat triple-negative breast cancer metastasis.